Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2000 September;44(3) > The Quarterly Journal of Nuclear Medicine 2000 September;44(3):208-23

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Share

 

  RADIOPHARMACOLOGY 

The Quarterly Journal of Nuclear Medicine 2000 September;44(3):208-23

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Gene transfer strategies for improving radiolabeled peptide imaging and therapy

Rogers B. E., Zinn K. R., Buchsbaum D. J.

From the Departments of Radiation Oncology and *Radiology University of Alabama at Birmingham, Birmingham, AL, USA


PDF


Utilization of molec­u­lar biol­o­gy tech­niques ­offers attrac­tive ­options in nucle­ar med­i­cine for improv­ing can­cer imag­ing and ther­a­py ­with radio­lab­eled pep­tides. Two of ­these ­options ­include util­iza­tion of ­phage-pan­ning to iden­ti­fy nov­el ­tumor-spe­cif­ic pep­tides or sin­gle ­chain anti­bod­ies and ­gene trans­fer tech­niques to ­increase the num­ber of anti­gen/recep­tor ­sites ­expressed on malig­nant ­cells. Our ­group has ­focused on the lat­ter ­approach for improv­ing radio­lab­eled pep­tide imag­ing and ther­a­py. The ­most wide­ly ­used ­gene trans­fer vec­tors in clin­i­cal ­gene ther­a­py ­trials ­include ret­ro­vi­rus, cat­ion­ic lip­ids, and aden­o­vi­rus. We ­have uti­lized aden­o­vi­rus vec­tors for ­gene trans­fer ­because of ­their abil­ity to accom­plish effi­cient in vivo ­gene trans­fer. Adenovirus vec­tors encod­ing the ­genes for a varie­ty of anti­gens/recep­tors (car­cin­oem­bryon­ic anti­gen, gas­trin-releas­ing pep­tide recep­tor, som­a­tos­ta­tin recep­tor sub­type 2 (SSTr2)) ­have all ­shown ­that ­their expres­sion is ­increased on can­cer ­cells ­both in ­vitro and in ­vivo fol­low­ing aden­o­vi­rus infec­tion. Of par­tic­u­lar inter­est has ­been the aden­o­vi­rus encod­ing for SSTr2 (AdCMVSSTr2). Various radio­iso­topes ­have ­been ­attached to som­a­tos­ta­tin ana­logues for imag­ing and ther­a­py of SSTr2-pos­i­tive ­tumors ­both clin­i­cal­ly and in ani­mal mod­els. The use of ­these ana­logues in com­bi­na­tion ­with AdCMVSSTr2 is a prom­is­ing ­approach for improv­ing the detec­tion sen­si­tiv­ity and ther­a­peu­tic effi­ca­cy of ­these radio­lab­eled pep­tides ­against sol­id ­tumors. In addi­tion, we ­have pro­posed the use of SSTr2 as a mark­er for imag­ing the expres­sion of ­another can­cer ther­a­peu­tic trans­gene (e.g. cyto­sine deam­i­nase, thy­mi­dine ­kinase) encod­ed with­in the ­same vec­tor. This ­would ­allow for non-inva­sive mon­i­tor­ing of ­gene deliv­ery to ­tumor ­sites.

inizio pagina